China SXT Pharmaceuticals is no longer being priced as a Taizhou maker of traditional Chinese medicine pieces. The public story is a British Virgin Islands listing that keeps selling stock to stay listed while the underlying plant keeps shrinking. Results for the year ended in late March show a third consecutive contraction in the product book, and the higher-margin advanced line that once justified the specialty-pharma label has almost disappeared. What remains is a cash pile built from equity sales, a single customer that now carries nearly all of the remaining volume, and a capital-markets calendar that has become the actual operating system.
The plant did not lose a price war so much as it lost demand. Regular pieces still account for almost the entire book, yet even that line contracted by a quarter. Advanced pieces, the ready-to-swallow and after-soaking products that used to carry the better margin, fell by more than four fifths and now contribute only a sliver of sales. Headline losses widened because of a large one-time employee incentive inside general and administrative expense, not because the factory suddenly spent more on herbs. Cash at year-end still sits far above the current market value of the equity. That gap is the entire bull case, and it is also the trap: most of the cash sits in renminbi at the variable-interest entity, and the parent keeps issuing paper anyway.
After the fiscal year closed, management layered a dual-class recap, two artificial-intelligence press campaigns, a registered direct sale of units with attached warrants, a prepaid-purchase line with a Hong Kong counterparty, an at-the-market ceiling, an eighty-to-one consolidation, and then a floor-price reset that put the convertible math back where it started. The next test is not whether Taizhou can invent a software story. It is whether Regular pieces stop shrinking, whether the dominant customer stays, and whether the listing stops manufacturing shares faster than the plant can earn.